BioBridge Global Executive and Leadership Team

Donna Respondek, the Executive Vice President & Chief Financial Officer at BioBridge Global, manages the fiscal health and long-term financial strategy of the organization. Respondek oversees capital allocation, budgeting, and financial reporting to ensure the sustainability of blood and tissue banking operations. By analyzing market trends and operational costs, the Chief Financial Officer provides the necessary data to support strategic investments in new medical technologies. This leadership role involves collaborating with the board to maintain financial transparency and regulatory compliance across all subsidiaries. Donna Respondek drives growth by identifying opportunities for cost optimization and revenue diversification within the healthcare sector. Through disciplined financial management, the Executive Vice President & Chief Financial Officer secures the resources required to expand the reach of the organization, ultimately strengthening the ability to provide essential biological services to patients and healthcare partners throughout the region.

John Youngdahl, the Senior Vice President & Chief Financial Officer at BioBridge Global, directs the financial planning and risk management strategies that underpin the organization's growth. Youngdahl oversees the financial health of the enterprise, ensuring that capital investments align with the long-term mission of supporting blood and tissue banks. By monitoring economic indicators and operational performance metrics, the Chief Financial Officer provides actionable insights to the executive team. This leadership role involves managing financial audits, treasury functions, and investor relations to maintain institutional credibility. John Youngdahl drives fiscal responsibility by implementing robust financial controls and optimizing resource allocation across all business units. Through the strategic oversight of the company's financial architecture, the Senior Vice President & Chief Financial Officer ensures that the organization remains well-positioned to navigate the complexities of the healthcare market while continuing to invest in the infrastructure necessary for future success.

Mark Fite, the Executive Vice President BioBridge Global, Chief Operating Officer South Texas Blood and Tissue and QualTex Laboratories at BioBridge Global, directs the operational integrity of critical blood and tissue supply chains. Fite manages the complex logistics required to maintain high-quality standards across South Texas Blood & Tissue Center and QualTex Laboratories. By optimizing laboratory workflows and donor collection processes, the Executive Vice President ensures consistent availability of life-saving biological products. This leadership role involves coordinating cross-functional teams to meet stringent regulatory requirements while scaling production capabilities to support regional healthcare providers. Mark Fite drives efficiency through rigorous process improvement initiatives, ensuring that the organization remains a leader in the biotechnology sector. Through strategic oversight of these vital assets, the Executive Vice President maintains the operational excellence necessary to support the broader mission of the organization in the competitive landscape of medical diagnostics and tissue banking.

Taylor Audra, the Senior Vice President, BioBridge Global and Chief Operating Officer, South Texas Blood and Tissue at BioBridge Global, leads the strategic execution of community-based blood collection and distribution programs. Audra manages the daily operations of the South Texas Blood & Tissue Center, ensuring that donor engagement and supply chain reliability meet the needs of local hospitals. By implementing advanced inventory management systems, the Chief Operating Officer maintains a steady supply of blood products for critical care environments. This leadership role involves fostering partnerships with community organizations to increase donor participation and awareness. Taylor Audra drives operational improvements that enhance the speed and safety of blood delivery services. Through the coordination of regional initiatives, the Senior Vice President, BioBridge Global and Chief Operating Officer, South Texas Blood and Tissue ensures that the organization remains responsive to the evolving demands of the healthcare community while maintaining the highest standards of quality and service.

Geoffrey Kindt, the Interim Senior Vice President, Chief Operating Officer at BioBridge Global, directs the day-to-day operational functions to ensure seamless service delivery across the organization. Kindt oversees the integration of internal processes, focusing on enhancing productivity and operational agility within the blood and tissue banking network. By streamlining communication between departments, the Chief Operating Officer facilitates a cohesive approach to managing complex biological assets. This leadership role involves identifying bottlenecks in service delivery and implementing scalable solutions to improve overall performance. Geoffrey Kindt drives organizational stability by maintaining focus on core business objectives during periods of transition. Through the application of rigorous operational standards, the Interim Senior Vice President, Chief Operating Officer supports the broader mission of the company, ensuring that all departments remain aligned with the strategic goals of the organization while delivering high-quality results to healthcare partners and patients.

Adrienne Mendoza, the Chief Operating Officer, BBG Advanced Therapies at BioBridge Global, leads the development and commercialization of innovative cell and gene therapy solutions. Mendoza oversees the specialized infrastructure required for advanced therapeutic manufacturing, ensuring compliance with complex regulatory frameworks. By bridging the gap between research and clinical application, the Chief Operating Officer accelerates the delivery of cutting-edge treatments to patients in need. This leadership role involves managing high-tech laboratory operations and coordinating with clinical partners to advance the pipeline of regenerative medicine products. Adrienne Mendoza drives innovation by fostering a culture of technical excellence and precision within the Advanced Therapies division. Through the strategic management of these specialized assets, the Chief Operating Officer, BBG Advanced Therapies positions the organization at the forefront of the biotechnology industry, expanding the impact of the company beyond traditional blood and tissue banking into the future of personalized medicine.

Rachel Beddard, the Chief Medical Officer at BioBridge Global, provides clinical leadership and oversight for all medical activities within the organization. Beddard ensures that blood and tissue banking practices adhere to the highest standards of patient safety and medical ethics. By guiding the development of clinical protocols, the Chief Medical Officer maintains the integrity of the biological products supplied to healthcare providers. This leadership role involves collaborating with medical boards and regulatory agencies to stay at the forefront of transfusion medicine and tissue transplantation. Rachel Beddard drives quality assurance by implementing evidence-based practices across all clinical operations. Through the continuous evaluation of medical outcomes, the Chief Medical Officer supports the organization's commitment to excellence, ensuring that every product and service provided meets the rigorous demands of the medical community while prioritizing the health and safety of donors and recipients alike.

Rachel-Louise Beddard, the Senior Vice President, Chief Medical Officer at BioBridge Global, directs the strategic medical initiatives that define the organization's clinical impact. Beddard oversees the integration of medical research into operational workflows, ensuring that the company remains a leader in the field of regenerative medicine and blood banking. By providing expert guidance on clinical strategy, the Chief Medical Officer facilitates the adoption of new technologies that improve patient outcomes. This leadership role involves managing relationships with medical professionals and overseeing the clinical governance of all tissue and blood programs. Rachel-Louise Beddard drives innovation by championing research projects that expand the therapeutic potential of the organization's biological assets. Through the application of deep medical expertise, the Senior Vice President, Chief Medical Officer ensures that the company maintains its reputation for clinical excellence, providing essential support to healthcare systems and patients through advanced medical science and rigorous safety standards.